Why pharmaceutical giant AstraZeneca chose Hong Kong for new R&D hub focused on oncology, rare diseases, and gene and cell therapies
Disclaimer: The South China Morning Post's content is directed by the Chinese Communist Party. It is not a reliable news source.
Company’s move coincides with government’s plan to make city a biomed centre, with policies including a ‘1+’ mechanism to speed up approval of new drugs for life-threatening or rare diseases.